These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 32808736

  • 41. A case of percutaneous septal myocardial ablation in a patient with obstructive hypertrophic cardiomyopathy with accessory mitral valve tissue.
    Eto H, Uzu K, Nagasawa Y, Shimokawa Y, Okubo H, Shimizu H.
    J Cardiol Cases; 2024 Jan; 29(1):39-42. PubMed ID: 38188315
    [Abstract] [Full Text] [Related]

  • 42. Percutaneous alcohol septal ablation for hypertrophic obstructive cardiomyopathy: technical review and long-term clinical and echocardiographic outcomes.
    Leal S, Galeote G, Jiménez-Valero S, Sánchez-Recalde A, Salinas P, Ruiz AS, Orbe LC, Dominguéz F, Moreno R, López-Sendón JL.
    Rev Port Cardiol; 2012 May; 31(5):363-71. PubMed ID: 22482474
    [Abstract] [Full Text] [Related]

  • 43. Short-term results of alcohol septal ablation as a bail-out strategy to treat severe left ventricular outflow tract obstruction after transcatheter mitral valve replacement in patients with severe mitral annular calcification.
    Guerrero M, Wang DD, Himbert D, Urena M, Pursnani A, Kaddissi G, Iyer V, Salinger M, Chakravarty T, Greenbaum A, Makkar R, Vahanian A, Feldman T, O'Neill W.
    Catheter Cardiovasc Interv; 2017 Dec 01; 90(7):1220-1226. PubMed ID: 28266162
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Review on sudden death risk reduction after septal reduction therapies in hypertrophic obstructive cardiomyopathy.
    Rigopoulos AG, Ali M, Abate E, Matiakis M, Melnyk H, Mavrogeni S, Leftheriotis D, Bigalke B, Noutsias M.
    Heart Fail Rev; 2019 May 01; 24(3):359-366. PubMed ID: 30617667
    [Abstract] [Full Text] [Related]

  • 46. [Role of cardiac magnetic resonance on predicting outcome in patients with hypertrophic obstructive cardiomyopathy undergoing percutaneous transluminal septal myocardial ablation].
    Du H, Lu M, Yin G, Yin X, Jiang Y, Wang J, Chen X, Song L, Huang J, Zhang Y, Zhao S.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Aug 01; 42(8):665-9. PubMed ID: 25388340
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging.
    van Dockum WG, ten Cate FJ, ten Berg JM, Beek AM, Twisk JW, Vos J, Hofman MB, Visser CA, van Rossum AC.
    J Am Coll Cardiol; 2004 Jan 07; 43(1):27-34. PubMed ID: 14715178
    [Abstract] [Full Text] [Related]

  • 49. [Comparison of early clinical effects of ablation with surgery treatment in patients with hypertrophic cardiomyopathy].
    Ruan YP, Liu XW, Zhang Y, Han JC, Lai YQ, Lü J, He YH.
    Zhonghua Yi Xue Za Zhi; 2017 Dec 05; 97(45):3553-3557. PubMed ID: 29275594
    [Abstract] [Full Text] [Related]

  • 50. Left ventricular longitudinal systolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a long-term follow-up study focused on speckle tracking echocardiography.
    Sommer A, Poulsen SH, Mogensen J, Thuesen L, Egeblad H.
    Eur J Echocardiogr; 2010 Dec 05; 11(10):883-8. PubMed ID: 20667848
    [Abstract] [Full Text] [Related]

  • 51. Cardiac electromechanical mapping in analyzing the mechanism of left ventricular remodeling immediately after percutaneous transluminal septal ablation in patients with hypertrophic obstructive cardiomyopathy.
    Chen SL, Huang J, Ye F, Shan SJ, Zhang JJ, Duan BX, Chen YD.
    Chin Med J (Engl); 2005 Nov 05; 118(21):1779-85. PubMed ID: 16336814
    [Abstract] [Full Text] [Related]

  • 52. Percutaneous transluminal septal myocardial ablation was effective in hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles: a case report.
    Yuzawa-Tsukada N, Tokuda M, Miyamoto T, Yoshimura M.
    Eur Heart J Case Rep; 2023 Jan 05; 7(1):ytac493. PubMed ID: 36694877
    [Abstract] [Full Text] [Related]

  • 53. Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy.
    Burghardt A, van Buuren F, Dimitriadis Z, Grübbel T, Seggewiss H, Scholtz S, Horstkotte D, Faber L.
    Clin Res Cardiol; 2018 Jun 05; 107(6):479-486. PubMed ID: 29453593
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. MR imaging evaluation of regional, remote, and global effects of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy.
    Amano Y, Takayama M, Kumita S, Kumazaki T.
    J Comput Assist Tomogr; 2007 Jun 05; 31(4):600-4. PubMed ID: 17882040
    [Abstract] [Full Text] [Related]

  • 57. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy.
    Seggewiss H, Faber L, Gleichmann U.
    Thorac Cardiovasc Surg; 1999 Apr 05; 47(2):94-100. PubMed ID: 10363608
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy.
    Liu L, Li J, Zuo L, Zhang J, Zhou M, Xu B, Hahn RT, Leon MB, Hsi DH, Ge J, Zhou X, Zhang J, Ge S, Xiong L.
    J Am Coll Cardiol; 2018 Oct 16; 72(16):1898-1909. PubMed ID: 30309466
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.